

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: TMI201868

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Traverse Therapeutics, Inc.		08/31/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Company Name:	Mirum Pharmaceuticals, Inc.		
Street Address:	950 Tower Lane		
Internal Address:	Suite 1050		
City:	Foster City		
State/Country:	CALIFORNIA		
Postal Code:	94404		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	97911202	CYPKEENA	
Serial Number:	97911205	ONKEETX	
Serial Number:	77652286	CHENODAL	
Serial Number:	85884088	CHOLBAM	
CORRESPONDENCE DATA			
Fax Number:	2127046288		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(212)704-6125		
Email:	trademarks@troutman.com,Karl.Zielaznicki@troutman.com		
Correspondent Name:	Mr. Karl M. Zielaznicki		
Address Line 1:	600 Peachtree Street, NE, Suite 3000		
Address Line 4:	Atlanta, GEORGIA 30308		
ATTORNEY DOCKET NUMBER:	254409.000363		
NAME OF SUBMITTER:	Eliza Cen		
SIGNATURE:	Eliza Cen		
DATE SIGNED:	05/01/2024		
Total Attachments: 20			

CH \$115.00.00 97911202

source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page1.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page2.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page3.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page4.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page5.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page6.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page7.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page8.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page9.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page10.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page11.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page12.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page13.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page14.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page15.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page16.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page17.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page18.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page19.tif
source=[FINAL MERGE] Travers Assignment of Intellectual Property Executed#page20.tif

AMENDMENT TO ASSIGNMENT OF INTELLECTUAL PROPERTY

This **AMENDMENT TO ASSIGNMENT OF INTELLECTUAL PROPERTY** (this “Amendment to IP Assignment”) effective August 31, 2023 (the “Effective Date”) by and between Travers Therapeutics, Inc., a Delaware corporation with an address at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (“Assignor”) and Mirum Pharmaceuticals, Inc., a Delaware corporation with an address at 950 Tower Lane, Suite 1050, Foster City, CA 94404 (“Assignee”). Assignor and Assignee are individually referred to herein as a “Party,” and collectively as the “Parties.”

WHEREAS, Assignor and Assignee previously entered into an Asset Purchase Agreement dated July 16, 2023 (as may be amended from time to time, the “Purchase Agreement”) and an Assignment of Intellectual Property effective August 31, 2023 (as may be amended from time to time, the “IP Assignment”);

WHEREAS, in connection with the Purchase Agreement and pursuant to the IP Assignment, Assignor hereby assigned, transfers and conveys to Assignee, all of Assignor’s worldwide right, title and interest in and to the in and to all of the Product IP, including without limitation, the Trademarks and Domain Names set forth on Attachment A attached thereto (collectively, as may be amended from time to time, the “Assigned IP”);

WHEREAS, subsequent to the execution of the IP Assignment, the Parties became aware of certain issues with Section 1. Transfer of Assigned IP of the IP Assignment and as to the scope and accuracy of the Assigned IP on Attachment A and have agreed amend Section 1 Transfer of Assigned IP and amend and replace Attachment A with a new listing of Assigned IP (the “Amended Attachment A”);

NOW, THEREFORE, pursuant to Purchase Agreement and the IP Assignment and in consideration of the promises and mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which is hereby, the Parties agree as follows:

1. Section 1, Transfer of Assigned IP of the IP Assignment is hereby amended and restated as follows:

Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee and its successors and assigns, and Assignee does hereby unconditionally accept: (a) all of Assignor’s right, title and interest in and to the Assigned IP and any and all goodwill in or relating to the same along with that portion of Assignor’s business in connection with which Assignor had a *bona fide* intention to use the Assigned IP including, without limitation, any Trademarks, to be held by Assignee for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns, designees, nominees and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; (b) all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to the Assignor with respect to any of the foregoing; (c) all claims, causes of action and enforcement rights, whether currently pending, filed, or otherwise, with respect to the Assigned IP, including all rights

to damages, injunctive relief and other remedies for past, current and future infringement of the Assigned IP; and (d) all other rights, privileges and protections of any kind whatsoever of Assignor accruing under any of the foregoing.

2. Attachment A of the IP Assignment is hereby amended and replaced with Amended Attachment A as annexed hereto.

3. The Parties expressly agree that all other provisions of the IP Assignment remain unaffected by this Amended IP Assignment.


4. This Amendment to IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement.

[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, the Parties have caused this Amendment to IP Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNOR:

TRAVERE THERAPEUTICS, INC.

By: 
Name: Elizabeth Reed
Title: SVP, General Counsel & Secretary

ACKNOWLEDGMENT


A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California
County of San Diego

On January 9, 2024 before me, C. M. Parenteau, Notary Public personally appeared Elizabeth Reed who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature  (Seal)



[Signature Page to Amendment to Assignment of Intellectual Property]

ASSIGNEE:

MIRUM PHARMACEUTICALS, INC.

By: [Signature]

Name: Christopher Peetz

Title: President and Chief Executive Officer

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California


County of San Mateo

On Feb 5, 2024 before me, Cynthia M. Lee, Deputy Public personally appeared Christopher Peetz who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature [Signature] (Seal)



[Signature Page to Amendment to Assignment of Intellectual Property]

Attachment A

Domain Names

1. AboutCTX.com
2. BehindtheBlur.com
3. Cholbam.com
4. CholbamHCP.com
5. LiverAtoZSD.com
6. UnderstandingPBD-ZSD.com
7. ZellwegerSpectrum.com
8. ZSDalliance.com
9. CTXrestore.com
10. Testcholestasis.com
11. Testctx.com
12. Cypkeena.com

Trademarks

CHOLBAM/KOLBAM

CHENODAL (wordmark)

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	204	5	77/652286	19-Jan-09	3755928	02-Mar-10	Registered	Renewal: 02-Mar-30
Goods: Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.								
Canada	206CA	5	1539219	10-Aug-11	TMA840759	21-Jan-13	Registered	Renewal: 21-Jan-28
Goods: Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.								



CHENODAL and Design

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	205	5	77/830559	20-Sep-09	4354250	18-Jun-13	Abandoned	n/a
Goods: Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof in oral dosage form for the treatment of gallstones and cerebrotendinous xanthomatosis.								
U.S.	288	5	88/936063	27-May-20			Abandoned	n/a
Goods: Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof for the treatment of gallstones.								

CHENODAL REBRANDING MARKS

CHEVANU

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	285	5	88/912432	12-May-20			Abandoned	n/a
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

CYPKEENA

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	284	5	88/912422	12-May-20			Abandoned	n/a
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

CYPTAKEE

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	287	5	88/912436	12-May-20			Abandoned	n/a
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								
U.S.	n/a	5	97/911,202	27-April-23			Pending	n/a
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

ONKEETX

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	286	5	88/912433	12-May-20			Abandoned	n/a
Goods:	Pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)							
U.S.	n/a	5	97/911,205	27-April-23			Pending	n/a
Goods:	Pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)							

Existing trademarks and trademark applications (Wordmark)

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	215	5	85/884088	22-Mar-13	4752361	09-Jun-15	Registered	Renewal: 09-Jun-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Argentina	226AR	5	3433793	18-Aug-15	2817870	12-Jul-16	Registered	Declaration of Use: 12-Jul-26
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Australia	215PAU	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Brazil	220BR	5	909857865	19-Aug-15	909857865	31-Oct-17	Registered	Renewal: 31-Oct-27
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Canada	225CA	5	1742193	18-Aug-15	TMA1032314	26-Jun-19	Registered	Renewal: 26-Jun-29
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Chile	221CL	5	1.166.449	14-Aug-15	1.202.404	15-Apr-16	Registered	Renewal: 15-Apr-26
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Colombia	215PCO	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Madrid Protocol	215WP	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Israel	215PIL	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Japan	215PJP	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Korea	215PKR	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								
Mexico	215PMX	5	A0052495	13-Aug-15			Abandoned	
Goods: Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.								

New Zealand	215PNZ	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Saudi Arabia	222SA	5	1437000861	25-Oct-15	1437000861	28-Feb-16	Registered	Renewal: 01-Jul-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Taiwan	224TW	5	104047933	14-Aug-15	01766681	01-May-16	Registered	Renewal: 30-Apr-26
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
United Arab Emirates	223AE	5	241379	07-Oct-15	241379	13-Jul-16	Registered	Renewal: 07-Oct-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							

ASSIGNMENT OF INTELLECTUAL PROPERTY

This **ASSIGNMENT OF INTELLECTUAL PROPERTY** (this “Assignment”) is made and entered into as of August 31, 2023 (the “Effective Date”) by and between Travers Therapeutics, Inc., a Delaware corporation with an address at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (“Assignor”) and Mirum Pharmaceuticals, Inc., a Delaware corporation with an address at 950 Tower Lane, Suite 1050, Foster City, CA 94404 (“Assignee”). Assignor and Assignee are individually referred to herein as a “Party,” and collectively as the “Parties.”

WHEREAS, Assignor and Assignee have entered into the Asset Purchase Agreement dated July 16, 2023 (as may be amended from time to time, the “Purchase Agreement”);

WHEREAS, capitalized terms used and not otherwise defined herein have the meanings ascribed thereto in the Purchase Agreement;

WHEREAS, in connection with the Purchase Agreement, the parties to the Purchase Agreement desire that Assignor transfer to Assignee all of the right, title and interest of Assignor in and to the Product IP, including without limitation the Trademarks and Domain Names set forth on Attachment A attached hereto (collectively, the “Assigned IP”); and

WHEREAS, Assignee wishes to acquire all of Assignor’s right, title and interest in and to the Assigned IP, and Assignor wishes to assign such right, title and interest in and to such Assigned IP to Assignee.

NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:

1. Transfer of Assigned IP. Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee and its successors and assigns, and Assignee does hereby unconditionally accept: (a) all of Assignor’s right, title and interest in and to the Assigned IP; (b) all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to the Assignor with respect to any of the foregoing; (c) all claims, causes of action and enforcement rights, whether currently pending, filed, or otherwise, with respect to the Assigned IP, including all rights to damages, injunctive relief and other remedies for past, current and future infringement of the Assigned IP; and (d) all other rights, privileges and protections of any kind whatsoever of Assignor accruing under any of the foregoing.

2. Proxy Service and Electronic Transfer for Domain Names. Assignor hereby authorizes and requests, or will cause any proxy service that registered any of the domain names included in the Assigned IP on Assignor’s behalf to authorize or request, the applicable registration authority to transfer such domain names from Assignor or such proxy service, as the case may be, to Assignee. Assignor agrees to cooperate with Assignee to initiate and complete the transfer process in relation to such domain names electronically from Assignor’s account to Assignee’s account and servers.

3. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, at Assignee's expense, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned IP in Assignee, its successors and assigns. Assignor hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks of the United States Patent and Trademark Office, the Commissioner for Copyrights of the United States Copyright Office and any other Governmental Entity to record and register this Assignment upon request by Assignee. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead solely to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance and perfection of patent, trademark, copyright or other intellectual property registrations or any other legal protection thereon with the same legal force and effect as if executed by such Assignor.

4. Entire Agreement. This Assignment and the Purchase Agreement reflect the entire understanding of the Parties relating to the sale, assignment, transfer, conveyance and delivery of the Assigned IP from Assignor to Assignee, and supersede all prior agreements, understandings or letters of intent between or among the Parties regarding the subject matter of this Assignment and the Purchase Agreement.

5. Successors and Assigns. This Assignment shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

6. Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to any conflict of law principles.

7. Arbitration of Disputes. Section 10.8 of the Purchase Agreement is hereby incorporated by reference *mutatis mutandis*.

8. Severability. Whenever possible, each provision or portion of any provision of this Assignment shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Assignment is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Assignment shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.

9. Counterparts. This Assignment may be executed in several counterparts, each of which will constitute an original and all of which, when taken together, will constitute one agreement. This Assignment may be executed by .PDF or by other means of electronic signature (including DocuSign), and the exchange of a fully executed Assignment (in counterparts or otherwise) by electronic means in .PDF format shall in each case create a valid and binding obligation of the Party executing the same.

10. Purchase Agreement Shall Control. Nothing in this Assignment shall change, amend, limit, extend or alter (nor shall it be deemed or construed as changing, amending, extending or altering) the terms or conditions of the Purchase Agreement or any liability or obligation of the Assignor or Assignee arising under the Purchase Agreement, which shall govern the representations, warranties and obligations of the Parties with respect to the Assigned IP. The terms of the Purchase Agreement are incorporated herein by this reference, and in the event that any of the provisions of this Assignment are determined to conflict with the terms of the Purchase Agreement, the terms of the Purchase Agreement shall control.

[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNOR:

TRAVERE THERAPEUTICS, INC.

By: Eric Dube

Name: Eric Dube

Title: President and Chief Executive Officer

[Signature Page to Assignment of Intellectual Property]

**TRADEMARK
REEL: 008417 FRAME: 0178**

ASSIGNEE:

MIRUM PHARMACEUTICALS, INC.

By: CP

Name: Christopher Peetz

Title: President and Chief Executive Officer

[Signature Page to Assignment of Intellectual Property]

**TRADEMARK
REEL: 008417 FRAME: 0179**

Attachment A

Domain Names

1. AboutCTX.com
2. BehindtheBlur.com
3. Cholbam.com
4. CholbamHCP.com
5. LiverAtoZSD.com
6. UnderstandingPBD-ZSD.com
7. ZellwegerSpectrum.com
8. ZSDalliance.com
9. CTXrestore.com
10. Testcholestasis.com
11. Testctx.com
12. Cypkeena.com

Trademarks

CHOLBAM/KOLBAM

CHENODAL (wordmark)

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	204	5	77/652286	19-Jan-09	3755928	02-Mar-10	Registered	Renewal: 02-Mar-30
Goods: Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.								
Canada	206CA	5	1539219	10-Aug-11	TMA840759	21-Jan-13	Registered	Renewal: 21-Jan-28
Goods: Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.								

CHENODAL and Design



Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	205	5	77/830559	20-Sep-09	4354250	18-Jun-13	Abandoned	n/a
Goods: Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof in oral dosage form for the treatment of gallstones and cerebrotendinous xanthomatosis.								
U.S.	288	5	88/936063	27-May-20			Allowed	Statement of Use – FINAL: 10-Nov-23
Goods: Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof for the treatment of gallstones								

CHEMICAL REBRANDING MARKS**CHEVANU**

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	285	5	88/912432	12-May-20			Allowed	Statement of Use/5 th Extension Request: 27-Oct-23
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

CYPKEENA

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	284	5	88/912422	12-May-20			Allowed	Statement of Use/5 th Extension Request: 27-Oct-23
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

CYPTAKEE

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	287	5	88/912436	12-May-20			Allowed	Statement of Use/5 th Extension Request: 27-Oct-23
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

ONKEFTX

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	286	5	88/912433	12-May-20			Allowed	Statement of Use/5 th Extension Request: 27-Oct-23
Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)								

Existing trademarks and trademark applications (Wordmark)

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	215	5	851884088	22-Mar-13	4752361	09-Jun-15	Registered	Renewal: 09-Jun-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
European Union	216EM	5	011686177	25-Mar-13	011686177	22-Aug-13	Registered	Renewal: 25-Mar-23
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
United Kingdom	216GB	5	011686177	25-Mar-13	UK00911686177	22-Aug-13	Registered	Renewal: 25-Mar-23
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Argentina	226AR	5	3433793	18-Aug-15	2817870	12-Jul-16	Registered	Declaration of Use: 12-Jul-26
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Australia	215PAU	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Brazil	220BR	5	909857865	19-Aug-15	909857865	31-Oct-17	Registered	Renewal: 31-Oct-27
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Canada	225CA	5	1742193	18-Aug-15	TMA1032314	26-Jun-19	Registered	Renewal: 26-Jun-29
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Chile	221CL	5	1166449	14-Aug-15	1166449	15-Apr-16	Registered	Renewal: 15-Apr-26
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Colombia	215PCO	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Madrid Protocol	215WP	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Israel	215PIL	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Japan	215JPJ	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Korea	215PKR	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Mexico	215PMX	5	A0052495	13-Aug-15			Abandoned	
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							

New Zealand	215PNZ	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-Aug-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Saudi Arabia	222SA	5	1437000861	25-Oct-15	1437000861	28-Feb-16	Registered	Renewal: 01-Jul-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
Taiwan	224TW	5	104047933	14-Aug-15	01766681	01-May-16	Registered	Renewal: 30-Apr-26
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							
United Arab Emirates	223AE	5	241379	07-Oct-15	241379	13-Jul-16	Registered	Renewal: 07-Oct-25
Goods:	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.							

TRADEMARK

REEL: 008417 FRAME: 0184

RECORDED: 05/01/2024